EBS - Emergent BioSolutions Inc.
Close
8.1
-0.020 -0.247%
Share volume: 7,745
Last Updated: Fri 27 Dec 2024 05:29:46 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$8.12
-0.02
-0.25%
Fundamental analysis
16%
Profitability
2%
Dept financing
18%
Liquidity
17%
Performance
29%
Performance
5 Days
1.84%
1 Month
-17.25%
3 Months
14.01%
6 Months
26.52%
1 Year
244.40%
2 Year
-24.55%
Key data
Stock price
$8.10
DAY RANGE
$7.95 - $8.35
52 WEEK RANGE
$1.58 - $15.10
52 WEEK CHANGE
$236.03
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Robert G. Kramer
Region: US
Website: emergentbiosolutions.com
Employees: 2,420
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: emergentbiosolutions.com
Employees: 2,420
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Emergent BioSolutions focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose.
Recent news